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Abstract: Invasive fungal infections are a major cause of morbidity and mortality in 
immunocompromised patients, such as subjects with hematological malignancies and patients 
who underwent to hematopoietic stem cell transplantation (HSCT) or solid organ transplanta-
tion (SOT). Fusarium spp. cause a broad spectrum of infections in humans. Immunologically 
competent hosts show mainly localized skin infections, whereas disseminated fusariosis occurs 
almost exclusively in immunocompromised patients. Fusarium spp. are resistant to many anti-
fungal agents with equivocal in vitro and in vivo susceptibility to amphotericin B. Voriconazole 
(VRC) is a triazole shown to be safe, well tolerated, and in vitro efﬁ  cacious against Fusarium 
spp. Although clinical experience is limited, many case reports have shown the efﬁ  cacy of VRC 
in the treatment of fusariosis.
Keywords: fusariosis, voriconazole, immunocompromised patient, cancer, fungal infections, 
aspergillus
Introduction
Invasive fungal infections are a major cause of mortality from infection in immuno-
compromised patients with hematological malignancies, hematopoietic stem cell trans-
plantation (HSCT), and solid organ transplantation (SOT) (De Pauw et al 1999; Nucci 
2003; Nucci et al 2003). The introduction of ﬂ  uconazole prophylaxis in such patients 
has led to a shift in the epidemiology of fungal infections with a dramatic reduction 
of the incidence of candidiasis (Anaissie et al 1986; Boutati and Anaissie 1997; Marr 
et al 2002). By contrast, the incidence of mould infections such as aspergillosis and 
other non-aspergillar fungal infections has increased signiﬁ  cantly (Marr et al 2002; 
Walsh et al 2004). Among immunocompromised patients, invasive fusariosis is the 
second most common cause of mould infections after aspergillosis with an increasing 
incidence (Boutati and Anaissie 1997; Nucci 2003; Nucci et al 2004).
Fusarium spp. are plant pathogens and soil saprophytes that cause a broad spectrum 
of infections in humans, including superﬁ  cial (keratitis, onychomycosis), locally inva-
sive, and disseminated infection. Disseminated fusariosis occurs almost exclusively 
in immunocompromised individuals (Nucci et al 2002; Dignani et al 2004). Recently, 
Nucci et al reported the clinical characteristics and prognostic factors of 61 patients 
with fusariosis after HSCT (54 allogeneic HSCT, 7 autologous HSCT). The reported 
incidence of fusariosis ranged from 5 infections per 1000 HSCTs in human leucocyte 
antigen (HLA) matched related transplantations to 20 infections per 1000 HSCTs in HLA 
mismatched transplantations. The survival rate was 13%, with a median onset of 13 days 
from the diagnosis, and the single prognostic factor for death by multivariate analysis 
was persistent neutropenia (Nucci et al 2004). The incidence of invasive fungal infections 
is also increasing in SOT ranging between 5% and 20% (Lodato et al 2006), probably 
due to the use of more intense immunosuppression regimens to reduce acute allograft 
rejection. Between 1996 and 2007, 10 cases of fusariosis in patients who underwent Therapeutics and Clinical Risk Management 2007:3(6) 1166
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SOT were reported in literature. Nine of them were localized 
whereas one patient experienced disseminated fusariosis. The 
infection resolved in 9 of these patients. None died from fusari-
osis (Young and Meyers 1979; Heinz et al 1996; Arney et al 
1997; Girardi et al 1999; Linden et al 2000; Sampathkumar 
et al 2001; Cocuroccia et al 2003; Garbino et al 2004; Lodato 
et al 2005). Part of these data are presented in Table 1.
The incidence of fusariosis and its mortality rate are sig-
niﬁ  cantly higher in patients with hematological malignancies 
and in those with allogeneic HSCT due to more intense immu-
nosuppression and profound and prolonged neutropenia.  The 
genus Fusarium comprises a large number of species (more 
than 20) and the most common human pathogen is Fusarium 
solani isolated in approximately half of the reported infections. 
The remaining cases of human fusariosis are caused by 
Fusarium oxysporum, Fusarium moniliforme, and Fusarium 
verticillioides, each of which account for 10%–14% of all 
infections. Considering the increasing incidence of Fusarium 
spp. infections, an increased virulence of these species cannot 
be excluded (Nelson et al 1994; Nucci et al 2003).
Fusarium spp. manifest an inherent resistance to a 
multitude of antifungal agents, making the treatment of fusari-
osis a challenging task especially in severely immunosupressed 
individuals with hematological malignancies or transplant 
recipients. In this patient population fusariosis is frequently 
fatal (Al-Abdely 2003). Despite its equivocal in vitro suscepti-
bility and treatment failures (Arikan et al 1999), amphotericin 
B has remained the drug of choice for the management of dis-
seminated fusariosis (Guarro et al 1995). Voriconazole (VRC) 
is a triazole antifungal agent approved by the FDA in May 2002 
for the treatment of fungal infections including aspergillosis, 
cryptococcosis, scedosporiosis, and fusariosis since in vitro 
data and clinical evidence indicated activity against Fusarium 
spp. (Arikan et al 1999; Espinel-Ingroff et al 2001; Paphitou 
et al 2002; Consigny et al 2003; Herbrecht 2004).
Treatment of fusariosis
Fusarium spp. can cause local and, most importantly, dissemi-
nated infections in immunocompromised patients with involve-
ment of multiple organs including the skin (Figure 1).
For the clinician taking care of patients with hematological 
malignancies disseminated fungal infections constitute one 
of the most difﬁ  cult challenges. In this patient population 
Fusarium spp. is an emerging cause of non-Aspergillus 
mould infection and is associated with high mortality. In 
1997 Boutati and Anaissie (Boutati and Anaissie 1997) 
described 43 patients with hematological malignancies 
who developed invasive Fusarium spp. infection. Thirteen 
of these (30%) responded to therapy with amphotericin B 
deoxycholate (AMBD) or its lipid formulations [liposomal 
amphotericin B (AmB-L); amphotericin B lipid complex 
(ABLC)]. The majority (70%) of patients died from the 
infection while a resolution was only seen in patients who 
ultimately recovered from cytopenia (Boutati and Anaissie 
1997; Kontoyiannis et al 2004). More recently, 84 cases 
of Fusarium spp. infection in patients with hematological 
malignancies were reported (Nucci 2003). Of them, only 
21% were alive 90 days after the diagnosis.
Polyenes
Current therapy for refractory invasive fungal infections 
caused by less-common moulds remains inadequate. 
Since fusariosis may mimic aspergillosis in its clinical 
manifestations, affected patients were usually treated with 
amphotericin B, an agent with poor activity in vitro against 
Fusarium spp. (Pfaller et al 2002), whereas evidence of a 
good in vivo activity is reported with ABLC (Lodato et al 
2006) and AmB-L (Jensen et al 2004; Selleslag 2006).
Azoles
Itraconazole
Itraconazole was demonstrated to exert negligible activity 
against Fusarium spp. (Pfaller et al 2000). It has rarely been 
administered against Fusarium spp. infections with unequi-
vocal results. Additionally it has been demonstrated that 
amphotericin B and VRC are consistantly more effective than 
itraconazole against Fusarium isolates (Lewis et al 2005). 
Itraconazole has seldom been administered for Fusarium 
infections with nonunivocal results (Reis et al 2000; Pereiro 
et al 2001; Cocuroccia et al 2003; Vincent et al 2003).
Voriconazole
VRC is an extended-spectrum, synthetic triazole derivative 
of ﬂ  uconazole, whose mechanism of action is inhibition of 
the cytochrome P450 (CYP)-dependent enzyme 14-α-sterol 
demethylase, preventing the fungal cell membrane synthesis 
and causing its disruption (Denning et al 2002; Ghannoum 
and Kuhn 2002; Johnson and Kauffman 2003; Herbrect 2004; 
Scott and Simpson 2007).
Intravenous and/or oral VRC is generally well tolerated. 
Nevertheless, approximately half of all subjects receiving 
VRC experienced at least one treatment-related adverse 
event (Ghannoum and Kuhn 2002; Alkan et al 2004; Herbrect 
2004; EMEA summary of product characteristics 2007; Scott 
and Simpson 2007).Therapeutics and Clinical Risk Management 2007:3(6) 1167
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Table 1 Cases of fusariosis found by a computerized search of MEDLINE and published from January 2000 to April 2007
Article, year   No.  Type  Pattern  Drug  Disease  Setting  Outcome
(Reference)            with  respect
            to  the  last
            drug
Linden et al 2000  1 not  spec.  - ABLC  -  SOT  resolved
Musa et al 2000  11 not  spec.  1 cutaneous  -  Diabetes  -  -
     1  cutaneous  -  Diabetes  -  -
     1  cutaneous  -  Diabetes  -  -
     1  cutaneous  AmB-L  NHL  CTH  resolved
     1  pneumonia  -  NHL  CTH  -
     1  pneumonia  AMBD  ALL  CTH  resolved
     1  disseminated  AMBD  HM  CTH  died
     1  disseminated  AMBD  HM  CTH  died
     1  disseminated  AmB-L  HM  CTH  died
     1  disseminated  AMBD,  AmB-L  HM  CTH  died
     1  disseminated  AMBD,  AmB-L  HM  CTH  died
Reis et al 2000  1  solani  keratitis Fluco,Itra,Vorico(iv, oral) -  -  resolved
Austen et al 2001  1  dimerum  disseminated AmB-L  ALL  CHT  died
Pereiro et al 2001  1  oxysporum cutaneous  Itra,  Fluco  -  -  improvement
Sampathkumar and   1 not  spec.  soft tissue  ABLC  Amyl  SOT  resolved
Paya 2001             
Bodey et al 2002  35  solani,   20 disseminated  Fluco 8  Cancer  8 BMT  -
   moniliforme,   15 localized  Itra 1     
   oxysporum,    AMBD,  AmB-L  8     
   proliferatum,   Other  18     
   dimerum         
Sponsel et al 2002  1  solani  endophthalmitis AMBD  + Keto, Posa  -  CL  resolved
Apostolidis et al 2003  1  not spec.  fungemia  AmB-L, Caspo  ALL  CHT  resolved
Cocuroccia et al 2003  1  solani cutaneous Itra  AS  SOT  improvement
Consigny et al 2003  1  not spec.  disseminated  AMBD, AmB-L,   AML  CHT  resolved
       Vorico(iv, oral)
Khoury and Ball 2003  1 not  spec. disseminated  AMBD  HM BMT  resolved
Perfect et al 2003  11 not  spec.  disseminated  Vorico(iv, oral)  HM CTH+BMT 45%  resp.
Rodriguez et al 2003  1  oxysporum disseminated  AmB-L  + Vorico(iv, oral) SAA  -  resolved
Vincent et al 2003  1  solani  disseminated ABCL,  Itra,  AmB-L,  AML CTH  resolved
       Vorico(iv, oral)
Garbino et al 2004  1 not  spec. peritonitis  Vorico(iv)  Diabetes SOT  resolved
Bigley et al 2004  1  dimerum disseminated AmB-L,  Vorico(iv, oral) SAA  BMT  resolved
Guimerá-MartÍn-Neda   1 not  spec. cutaneous  AmB-L,  Vorico FES  PDN  resolved
et al 2004             
Guzman-Cotrilli et al   1  solani  disseminated AmB-L  + Vorico(iv, oral) AML  CTH  improved
2004           
Hamaki et al 2004  1  solanii  disseminated AMBD  NHL BMT  died
Herbrecht et al 2004  1  proliferatum  pneumonia Posa  -  SOT  resolved
Jensen et al 2004  4 not  spec. disseminated  AmB-L  AML  CTH  resolved
   verticillioides disseminated  AMBD,  AmB-L  CLL  CTH  resolved
   verticillioides  disseminated AmB-L  AML CTH  resolved
   solani  disseminated AmB-L  NHL CTH  died
Kivivouri et al 2004  2  solani disseminated  AmB-L  ALL  BMT died
   not  spec.  disseminated -  AML BMT  died
Polizzi et al 2004  1  solani corneal  abscess  AMBD,  Vorico(iv + topical, oral) Abrasion -  resolved
Anandi et al 2005  1  solani cutaneous  Ketoconazole  (oral)  Diabetes  -  resolved
Cudillo et al 2005  1  not spec.  disseminated  AmB-L, Vorico (oral), AmB-L  ALL  CTH  died
Durand et al 2005  1  moniliforme  endophthalmitis AMBD(topical),  Vorico(oral) Catarct  -  resolved
Lodato et al 2005  1  solani liver  abscesses  ABLC  CD  SOT  resolved
Lin et al 2005  3  solani  keratitis Netamycin(ed)  -  - resolved
   solani  keratitis Netamycin(ed)  + Keto(oral)  -  -  resolved
   solani  keratitis Netamycin(ed)  + Fluco(oral)      resolved
Giaconi et al 2006  1  oxysporum keratitis  Vorico(topical)  - -  not  resolve
(Continued)Therapeutics and Clinical Risk Management 2007:3(6) 1168
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Table 1 (Continued)
Article, year   No.  Type  Pattern  Drug  Disease  Setting  Outcome
(Reference)             with  respect
              to the last
             drug
Gorman et al 20068  1  oxysporum  pneumonia  Vorico(oral)  - -  resolved
Hsu et al 2006  1 not  spec.  cutaneous  Vorico(oral)  NHL -  resolved
Madariaga and Kohl   1 not  spec.  disseminated  Vorico(iv)  Emph PDN -
2006           
Sagnelli et al 2006  1  verticillioides  disseminated  Vorico(iv, oral)  ST CTH  resolved
Selleslag 2006  1  solani disseminated  AmB-L  ALL CTH  resolved
Stanzani et al 2006  1  solani  disseminated AmB-L  + Vorico(iv, oral) AML  BMT  resolved
Bunya et al 2007  3 not  spec.  keratitis  Vorico(topical) -  -  resolved
   not  spec.  keratitis  Vorico(orlal + topical)  - -  resolved
   not  spec.  keratitis  Vorico(oral + topical)  - -  not  resolved
Tu et al 2007  3 not  spec.  endolphalmitis  AMBD(topical),  Vorico(iv), Posa  -  CL  resolved
   not  spec.  keratitis  AMBD(topical),  Vorico(topical + -  -  resolved
       oral), Posa
   not  spec.  endolphalmitis  Vorico(topical + iv, oral), Posa  -  CL  resolved
Abbreviations: ABLC, amphotericin B lipid complex; AmB-L, liposomal amphotericin B; AMBD, amphotericin B deoxycholate; ALL, acute lymphoblastic leukemia; AML, 
acute myeloid leukemia; Amyl, amyloidosis; AS, Alport syndrome; BMT, allogeneic bone marrow transplantation; Caspo, caspofungin; CD, Caroli’s disease; CHT, chemotherapy; 
CL, contact lens; ed, eye drops; Emph, emphysema; FES, Fisher-Evans syndrome; Fluco, ﬂ  uconazole; HD, Hodgkin disease; HM, hematological malignancies; Itra, itraconazole; 
Keto, ketoconazole; PDN, steroids; Posa, posaconazole; SOT, solid organ transplant; ST, solid tumor; Vorico, voriconazole.
In Candida spp. VRC is fungistatic, whereas in ﬁ  lamen-
tous organisms it is fungicidal. VRC shows in vitro activity 
against a variety of yeasts, ﬁ  lamentous fungi and dimorphic 
moulds. Candida spp., Aspergillus spp., Fusarium spp., and 
Scedosporium spp. are the pathogens against which VRC 
has been approved for treatment, whereas it has little or no 
activity against Zygomycetes.
Susceptibility of ﬁ  lamentous fungi to VRC was tested 
by 3 studies (Johnson et al 1998; Espinel-Ingroff et al 2001; 
Linres et al 2005). While Johnson and Espinel-Ingroff 
obtained minimum inhibitory concentrations (MICs) of 
between 2 and 8 µg/mL, more recently Linares et al showed 
that Fusarium spp. display greater susceptibility to VRC 
(MICs 0.25–4 µg/mL) than that reported before (Linares et al 
2005). Although animal data suggest a possible correlation 
between the efﬁ  cacy of VRC and MIC values, there was 
no correlation between clinical outcome and MIC values in 
clinical trials (EMEA 2007).
The efﬁ  cacy and safety of VRC for the primary treatment 
of invasive aspergillosis in immunocompromised patients 
has been described in randomized, non-blind, multinational 
trials and in observational studies (Denning et al 2002; 
Ghannoum and Kuhn 2002; Herbrecht et al 2002; Herbrecht 
2004; Alvarez-Lerma et al 2005; Mouas et al 2005; Scott 
and Simpson 2007), but also many case reports have 
shown the efﬁ  cacy of VRC in the treatment of fusariosis 
(Table 1) (Reis et al 2000; Consigny et al 2003; Perfect et al 
2003; Rodriguez et al 2003; Vincent et al 2003; Bigley et al 
2004; Garbino et al 2004; Guimerá-MartÍn-Neda et al 2004; 
Guzman-Cotrilli et al 2004; Polizzi et al 2004; Durand et al 
2005; Gorman et al 2006; Hsu et al 2006; Sagnelli et al 2006; 
Stanzani et al 2006; Bunya et al 2007). Thirty-four English 
language case reports were found by a computerized search 
of MEDLINE from January 2000 to April 2007. We found 
20 disseminated fusariosis and 14 localized infections: 
10 ocular involvements, 2 cutaneous lesions, 1 pneumonia, 
1 peritonitis. Hematological disease was the underlying 
setting in 18 patients, while solid tumor and chronic 
emphysema affected one patient each. All the patients with 
disseminated infection were immunodepressed because 
of chemotherapy, or HSCT, or steroids administration, 
as shown in Table 1. The overall response to VRC for 
disseminated fusariosis was 63% (12/19 evaluable). 
Treatment with VRC was initiated in 19 patients with the iv 
loading dose of 6 mg/kg bid, followed by the maintenance 
dose of 4 mg/kg bid. The switch to the oral treatment 
(200 mg bid) was made in 18 patients. Only one patient 
received the oral formulation of VRC from the start. 
For localized infections, VRC was administered iv to 5 
patients, eventually followed by oral administration for 
long-term maintenance. Topical VRC preparation could 
be added. In 6 patients oral voriconazole was administered 
from the beginning, while 2 patients received only topical 
formulations. In 3 patients with disseminated fusariosis, 
combined therapy consisting in voriconazole and AmB-
L was administered, while VRC was given as salvage Therapeutics and Clinical Risk Management 2007:3(6) 1169
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treatment in 4 patients with disseminated fusariosis (data 
shown in Table 1).
Recently, Perfect et al reported a multicenter, open-label, 
clinical study to assess the efﬁ  cacy and safety of VRC for 
the treatment of less-common, emerging or refractory inva-
sive fungal infections (Perfect et al 2003). Three-hundred 
and one immunocompromised patients were studied. The 
drug was administered iv at recommended dosages for at 
least 3 days, and the median duration of iv treatment was 
18 days (range 1–138 days). Thereafter patients could be 
switched to oral treatment. The median duration of oral 
administration was 69 days (range 1–326 days). In the 
study they treated 11 fusariosis, showing 45% of satisfac-
tory global response with respect to the high mortality 
rate (70%) for disseminated fusariosis treated with other 
therapies (Krcmery et al 1997; Boutati and Anaissie; Perfect 
et al 2003). These results were consistent with data from 
previous reports focused on the use of VRC in critically ill 
patients. They conﬁ  rm its good proﬁ  le concerning safety 
and tolerability, with an incidence of treatment-related 
toxicities, such as visual disturbances and rashes, requiring 
suspension for 3.5% of patients, but none of the toxicities 
were severe. Also liver function abnormalities were noted 
in 10% of patients, but only 2.4% had their treatment 
discontinued, conﬁ  rming previously reported data (Potoski 
and Brown 2002).
Posaconazole
Posaconazole (PSC) is a potent extended spectrum tiazole 
that has been shown to be highly active against yeasts and 
moulds, including Fusarium spp. (Espinel-Ingrof et al 2004; 
Torres et al 2005). Recently, Raad et al described a clinical 
experience with PSC utilized for refractory fusariosis or for 
patients intolerant to conventional antifungal therapy in 21 
cases, with an overall response of 48%. This result is compa-
rable with those seen with VRC, and prolonged neutropenia 
was an unfavorable risk factor of non-response (20% in 
patients who recovered from myelosuppression versus 67% 
in patients who did not recover) (Raad et al 2006). More-
over, 4 cases of ocular infection and 1 case of pneumonia 
by Fusarium spp. were described, treated and resolved with 
PSC after failure of treatment with VRC (iv, oral, and topical 
A
B
C
D
Figure 1 Patient with disseminated fusariosis and skin involvement. The lesions are seen most commonly on extremities and appear as widespread, violaceous (A) 
or erythematous indurated elements (B). With the resolution of the infection the skin lesions become darker (C) and the lesions disappear (D).Therapeutics and Clinical Risk Management 2007:3(6) 1170
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formulation) and other antifungal drugs (Sponsel et al 2002; 
Herbrecht et al 2004; Tue et al 2007).
PSC is administered as an oral suspension with food and 
this could limit its use in critically ill patients.
These results suggest PSC can be considered an appropriate 
alternative antifungal therapy to amphotericin B formulation, 
leading to results similar to those once found with VRC.
Echinocandins
Fusarium spp. are usually resistant to echinocandins by 
standard susceptibility testing (Spellberg et al 2006). Instead, 
a case of fungemia sustained by Fusarium spp. resistant to 
amphotericin B was resolved with caspofungin at standard 
doses in a patient with acute myeloid leukemia (Apostolidis 
et al 2003). A recent murine model disclosed that caspofungin 
at 1 mg/kg/day improved survival during active fusariosis, 
despite lack of reduction in fungal burden (Spellberg et al 
2006), suggesting a potential role in the treatment of human 
fusariosis.
Future perspectives
The in vitro interaction of itraconazole, amphotericin B 
and VRC with anidulafungin against Aspergillus spp. and 
Fusarium spp. was recently evaluated (Philip et al 2005). 
Figure 2 Biopsy of nodular skin lesion at the diagnosis (A) and after treatment (B).Therapeutics and Clinical Risk Management 2007:3(6) 1171
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Anidulafungin belongs to the echinocandins antifungal drugs 
class. The data showed that all drug combinations suggested 
indifference against Fusarium spp., but not antagonism or 
synergism. A previous study reported a potential synergistic 
to additive effect of caspofungin in combination with ampho-
tericin B against Fusarium spp. (Dismukes et al 2000). Also 
the combination of VRC and micafungin was tested showing 
a synergistic effect against Fusarium spp. (Heyn et al 2005), 
but clinical studies are needed to conﬁ  rm these data.
Nystatin is classiﬁ  ed among the most efﬁ  cient antifungal 
agents, widely used since 1950s, but insoluble in water. The 
in vitro activity of polymeric complexes of nystatin was 
investigated against growth inhibition and spore germina-
tion of Fusarium oxysporum. These complexes of nystatin 
were 3–25 times more active than nystatin against spore 
germination and were effective inhibitors of mycelial growth 
(Charvalos et al 2002). Their use in the clinical setting has 
not yet been investigated.
Conclusions
Invasive fusariosis is an emerging cause of mould infec-
tions in immunocompromised patients, with usually poor 
prognosis being Fusarium spp. resistant to most available 
antifungal agents (Nucci 2003). In vitro susceptibility test-
ing may be the only clue in the choice of the appropriate 
antifungal agent (Al-Abdely 2004). The only antifungal 
drugs effective against Fusarium spp., as evidenced by 
their relatively low MICs, are amphotericin B, nystatin, 
ketoconazole, VRC, and PSC (Espinel-Ingroff 1998; Lewis 
et al 2005; Teixeira et al 2005; Cuenca-Estrella et al 2006), 
whereas ﬂ  uconazole, itraconazole, and the echinocandins 
are not active alone against Fusarium spp. (Espinel-Ingroff 
1998; Marco et al 1998; Pfaller et al 1998; Lewis et al 
2005). VRC has a slightly broader spectrum of activity 
against most moulds, showing very good in vitro activity 
against Aspergillus spp., Fusarium spp., Scedosporium spp. 
(Denning et al 2003; Lewis et al 2005; Linares et al 2005). 
Many case reports have demonstrated the efﬁ  cacy of VRC 
in the treatment of fusariosis (Reis et al 2000; Consigny et al 
2003; Perfect et al 2003; Rodriguez et al 2003; Vincent et al 
2003; Bigley et al 2004; Garbino et al 2004; Guimerá-MartÍn-
Neda et al 2004; Guzman-Cotrilli et al 2004; Polizzi et al 
2004; Durand et al 2005; Gorman et al 2006; Hsu et al 2006; 
Sagnelli et al 2006; Stanzani et al 2006; Bunya et al 2007), 
with a 63% overall response for disseminated fusariosis, while 
Perfect et al reported a 45% satisfactory global response, with 
respect to the high mortality rate (70%) for patients treated 
with other antifungal drugs (Perfect et al 2003).
PSC is a new potent extended spectrum tiazole that has been 
shown to be active against Fusarium spp. (Espinel-Ingrof et al 
2004; Torres et al 2005; Raad et al 2006). However, no clini-
cal trials have hitherto compared PSC with VRC or addressed 
the relative use of these two broad spectrum tiazole agents 
in the management of fusariosis. Polymeric complexes of 
nystatin have been investigated against Fusarium oxysporum, 
but there have been no published clinical trials.
In conclusion, treatment of emerging invasive fungal 
infections is a major challenge, with no standardized therapy 
and high mortality rates. VRC seems to be the most promising 
antifungal agent for the treatment of disseminated fusariosis 
in immunocompromised subjects, but more clinical evidence 
is required.
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